Table 3.
NRTIs, NNRTIs, PIs, and INSTIs used during the study period
| Antiretroviral drug | Age, years
|
|||||||
|---|---|---|---|---|---|---|---|---|
| 2011
|
2012
|
2013
|
2014
|
2015
|
2016
|
2017
|
||
| NRTIs | (n=53) | (n=71) | (n=89) | (n=115) | (n=130) | (n=154) | (n=160) | |
|
| ||||||||
| ABC/3TC | Total | 12 (22.6) | 18 (25.4) | 28 (31.5) | 40 (34.8) | 42 (32.3) | 50 (32.5) | 55 (34.4) |
| <50 | 8 (15.1) | 11 (15.5) | 16 (18.0) | 22 (19.1) | 22 (16.9) | 28 (18.2) | 33 (20.6) | |
| ≥50 | 4 (7.5) | 7 (9.9) | 12 (13.5) | 18 (15.7) | 20 (15.4) | 22 (14.3) | 22 (13.8) | |
|
| ||||||||
| TDF/FTC | Total | – | 22 (31.0) | 32 (36.0) | 46 (40.0) | 77 (59.2) | 93 (60.4) | 45 (28.1) |
| <50 | – | 10 (14.1) | 16 (18.0) | 24 (20.9) | 39 (30.0) | 52 (33.8) | 27 (16.9) | |
| ≥50 | – | 12 (16.9) | 16 (18.0) | 22 (19.1) | 38 (29.2) | 41 (26.6) | 18 (11.3) | |
|
| ||||||||
| ZDV/3TC | Total | 29 (54.7) | 28 (39.4) | 27 (31.5) | 27 (23.5) | 7 (5.4) | 5 (3.2) | 4 (2.5) |
| <50 | 17 (32.1) | 15 (21.1) | 12 (13.5) | 11 (9.6) | 4 (3.1) | 2 (1.3) | 1 (0.6) | |
| ≥50 | 12 (22.6) | 13 (18.3) | 15 (18.0) | 16 (13.9) | 3 (2.3) | 3 (1.9) | 3 (1.9) | |
|
| ||||||||
| 3TC/d4T | Total | 7 (13.2) | – | – | – | – | – | – |
| <50 | 2 (3.8) | – | – | – | – | – | – | |
| ≥50 | 5 (9.4) | – | – | – | – | – | – | |
|
| ||||||||
| TAF/FTC | Total | – | – | – | – | – | – | 50 (31.3) |
| <50 | – | – | – | – | – | – | 26 (16.3) | |
| ≥50 | – | – | – | – | – | – | 24 (15.0) | |
|
| ||||||||
| 3TC/ddI | Total | 1 (1.9) | – | – | – | – | – | – |
| <50 | 1 (1.9) | – | – | – | – | – | – | |
| ≥50 | – | – | – | – | – | – | – | |
|
| ||||||||
| 3TC | Total | 3 (5.7) | – | – | – | – | ||
| <50 | 2 (3.8) | – | – | – | – | |||
| ≥50 | 1 (1.9) | – | – | – | – | – | – | |
|
| ||||||||
| Not used | Total | 1 (1.9) | 3 (4.2) | 2 (2.2) | 2 (1.7) | 4 (3.1) | 6 (3.9) | 6 (3.8) |
| <50 | 1 (1.9) | 2 (2.8) | 2 (2.2) | 2 (1.7) | 2 (1.5) | 3 (1.9) | 3 (1.9) | |
| ≥50 | – | 1 (1.4) | – | – | 2 (1.5) | 3 (1.9) | 3 (1.9) | |
|
| ||||||||
| NNRTIs | (n=13) | (n=14) | (n=10) | (n=15) | (n=15) | (n=28) | (n=14) | |
|
| ||||||||
| EFV | Total | 9 (69.2) | 11 (78.6) | 8 (88.9) | 13 (86.7) | 10 (66.7) | 2 (7.1) | – |
| <50 | 5 (38.5) | 6 (42.9) | 3 (30.0) | 5 (33.3) | 4 (26.7) | 1 (3.6) | – | |
| ≥50 | 4 (30.8) | 5 (35.7) | 5 (50.0) | 8 (53.3) | 6 (40.0) | 1 (3.6) | – | |
|
| ||||||||
| ETR | Total | 1 (7.7) | 3 (21.4) | 2 (20.0) | 2 (13.3) | 4 (26.7) | 6 (21.4) | 6 (42.9) |
| <50 | 1 (7.7) | 2 (14.3) | – | – | 3 (20.0) | 3 (10.7) | 3 (21.4) | |
| ≥50 | – | 1 (7.1) | – | – | 1 (6.7) | 3 (10.7) | 3 (21.4) | |
|
| ||||||||
| NVP | Total | 3 (23.1) | – | – | – | – | – | – |
| <50 | 2 (15.4) | – | – | – | – | – | – | |
| ≥50 | 1 (7.7) | – | – | – | – | – | – | |
|
| ||||||||
| RPV | Total | – | – | – | – | 1 (6.7) | 20 (71.4) | 8 (57.1) |
| <50 | – | – | – | – | – | 10 (35.7) | 4 (28.6) | |
| ≥50 | – | – | – | – | 1 (6.7) | 10 (35.7) | 4 (28.6) | |
|
| ||||||||
| PIs | (n=44) | (n=53) | (n=64) | (n=79) | (n=74) | (n=72) | (n=45) | |
|
| ||||||||
| ATV | Total | 13 (29.5) | 17 (32.1) | 19 (29.7) | 17 (21.5) | 6 (8.1) | 3 (4.2) | 1 (2.2) |
| <50 | 5 (11.4) | 9 (17.0) | 10 (15.6) | 9 (11.4) | 3 (4.1) | 1 (1.4) | 1 (2.2) | |
| ≥50 | 8 (18.2) | 8 (15.1) | 9 (14.1) | 8 (10.1) | 3 (4.1) | 2 (2.8) | – | |
|
| ||||||||
| ATV/RTV | Total | – | – | – | 7 (8.9) | 6 (8.1) | 4 (5.6) | 1 (2.2) |
| <50 | – | – | – | 4 (5.1) | 5 (6.8) | 4 (5.6) | 1 (2.2) | |
| ≥50 | – | – | – | 3 (3.8) | 1 (1.4) | – | – | |
|
| ||||||||
| ATV/COBI | Total | – | – | – | – | – | – | 2 (4.4) |
| <50 | – | – | – | – | – | – | 1 (2.2) | |
| ≥50 | – | – | – | – | – | – | 1 (2.2) | |
|
| ||||||||
| LPV/RTV | Total | 27 (61.4) | 30 (56.6) | 39 (60.9) | 45 (57.0) | 35 (47.3) | 33 (45.8) | 30 (66.7) |
| <50 | 18 (40.9) | 19 (35.8) | 24 (37.5) | 27 (34.2) | 19 (25.7) | 19 (26.4) | 17 (37.8) | |
| ≥50 | 9 (20.5) | 11 (20.8) | 15 (23.4) | 18 (22.8) | 16 (21.6) | 14 (19.4) | 13 (28.9) | |
|
| ||||||||
| DRV/RTV | Total | 1 (2.3) | 4 (7.5) | 4 (6.3) | 9 (11.4) | 26 (35.1) | 32 (44.4) | 7 (15.6) |
| <50 | 1 (2.3) | 3 (5.7) | 3 (4.7) | 7 (8.9) | 16 (21.6) | 20 (27.8) | 6 (13.3) | |
| ≥50 | – | 1 (1.9) | 1 (1.6) | 2 (2.5) | 10 (13.5) | 12 (16.7) | 1 (2.2) | |
|
| ||||||||
| DRV/COBI | Total | – | – | – | – | – | – | 4 (8.9) |
| <50 | – | – | – | – | – | – | 2 (4.4) | |
| ≥50 | – | – | – | – | – | – | 2 (4.4) | |
| IDV | Total | 3 (6.8) | 2 (3.8) | 2 (3.1) | 1 (1.3) | – | – | – |
| <50 | 2 (4.5) | 1 (1.9) | 1 (1.6) | – | – | – | – | |
| ≥50 | 1 (2.3) | 1 (1.9) | 1 (1.6) | 1 (1.3) | – | – | – | |
|
| ||||||||
| DRV | Total | – | – | – | – | 1 (1.4) | – | – |
| <50 | – | – | – | – | – | – | – | |
| ≥50 | – | – | – | – | 1 (1.4) | – | – | |
|
| ||||||||
| INSTIs | (n=1) | (n=10) | (n=20) | (n=26) | (n=51) | (n=65) | (n=112) | |
|
| ||||||||
| DTG | Total | – | – | – | – | 1 (2.0) | 11 (16.9) | 36 (32.1) |
| <50 | – | – | – | – | 1 (2.0) | 8 (12.3) | 22 (19.6) | |
| ≥50 | – | – | – | – | – | 3 (4.6) | 14 (12.5) | |
|
| ||||||||
| EVG/COBI | Total | – | – | – | – | 20 (39.2) | 30 (46.2) | 64 (57.1) |
| <50 | – | – | – | – | 12 (23.5) | 18 (27.7) | 34 (30.4) | |
| ≥50 | – | – | – | – | 8 (15.7) | 12 (18.5) | 30 (26.8) | |
|
| ||||||||
| RAL | Total | 1 (100.0) | 10 (100.0) | 20 (100.0) | 26 (100.0) | 30 (58.8) | 24 (36.9) | 12 (10.7) |
| <50 | 1 (100.0) | 2 (20.0) | 7 (35.0) | 9 (34.6) | 11 (21.6) | 8 (12.3) | 7 (6.3) | |
| ≥50 | – | 8 (80.0) | 13 (65.0) | 17 (65.4) | 19 (37.3) | 16 (24.6) | 5 (4.5) | |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; COBI, cobicistat; d4T, stavudine; ddI, didanosine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; FTC, emtricitabine; IDV, indinavir; INSTIs, integrase strand transfer inhibitors; LPV, lopinavir; NNRTIs, nonnucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.